Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & Co. Investors remain cautious as the pharma major nears its biggest-ever overseas acquisition amid debt concerns and volatile global conditions.
